Joincare Pharmaceutical Group disclosed its 2026 interim report. In the first half of the year, it achieved operating revenue of 6.583 billion yuan, down 16.66 percent year on year, and net profit attributable to shareholders of the listed company of 648 million yuan, down 17.49 percent year on year. The decline in performance mainly stemmed from its controlling subsidiary Livzon Pharmaceutical Group, whose operating revenue was about 5 billion yuan, down 20.28 percent year on year, and net profit attributable to the parent was 932 million yuan, down 27.23 percent year on year. The company's gross margin fell from 62.21 percent in the same period last year to 58.70 percent, and its net margin fell from 22.33 percent to 20.75 percent. Revenue from innovative drugs in the respiratory segment accounted for nearly 35 percent, while sales revenue in the health food segment was 304 million yuan, up 25 percent year on year.
Joincare Pharmaceutical Group Industry Co LtdFirst-half revenue and net profit declined significantly, with margins contracting.
Livzon Pharmaceutical Group IncControlling subsidiary's revenue and profit fell sharply, dragging overall performance.
